help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 8, 913-922, September 2006; doi:10.1634/theoncologist.11-8-913
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slattery, J. M.
Right arrow Articles by Sahani, D. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slattery, J. M.
Right arrow Articles by Sahani, D. V.

Hepatobiliary

What Is the Current State-of-the-Art Imaging for Detection and Staging of Cholangiocarcinoma?

James M. Slattery, Dushyant V. Sahani

Division of Abdominal Imaging and Interventional Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA

Key Words. Cholangiocarcinoma • Hepatectomy • Imaging • Resectability

Correspondence: Dushyant V. Sahani, M.D., Division of Abdominal Imaging and Interventional Radiology, 270 White Building, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-8386/8396; Fax: 617-726-4891; e-mail: dsahani{at}partners.org

Cholangiocarcinoma is an adenocarcinoma that arises from the bile duct epithelium and is the second most common primary hepatobiliary cancer, after hepatocellular cancer, with approximately 2,500 cases annually in the U.S. However, cholangiocarcinoma remains a relatively rare disease, accounting for <2% of all human malignancies. Although the entire biliary tree is potentially at risk, tumors involving the biliary confluence or the right or left hepatic ducts (hilar cholangiocarcinoma) are most common and account for 40%–60% of all cases. Most patients present with advanced disease that is not amenable to surgical treatment. The median survival time for patients with intrahepatic cholangiocarcinoma without involvement of the hilum varies among centers from 18–30 months. The median survival time for patients with perihilar cholangiocarcinoma is slightly less, varying from 12–24 months. Despite the overall poor prognosis, survival after surgical treatment of hilar cholangiocarcinoma has improved during the past 10–15 years. This review highlights the imaging features of cholangiocarcinoma, with particular emphasis on the imaging techniques that can best assess tumor resectability and guide the surgeon regarding the potential extent of resection required in operable candidates.




This article has been cited by other articles:


Home page
 RadioGraphicsHome page
N. I. Sainani, O. A. Catalano, N.-S. Holalkere, A. X. Zhu, P. F. Hahn, and D. V. Sahani
Cholangiocarcinoma: Current and Novel Imaging Techniques
RadioGraphics, September 1, 2008; 28(5): 1263 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. M. Welzel, K. A. McGlynn, A. W. Hsing, T. R. O'Brien, and R. M. Pfeiffer
Response: Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States
J Natl Cancer Inst, March 7, 2007; 99(5): 407 - 408.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.